Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Phase 2 results for autoimmune-related dry eye disease immunomodulator
➤ JCRS astigmatism working group publishes two papers
➤ FDA approves therapy for diabetic retinopathy
➤ Enrollment closes for largest retinal trial of its kind to date
➤ Enrollment complete for Phase 3 trial evaluating wet AMD treatment
➤ Rare Pediatric Disease Designation granted for treatment targeting several retinopathies
➤ ASCRS news and events
➤ Company to begin trial with dual-optic accommodative lens
➤ Phase 2 study to begin for immunoglobulin drops for dry eye
➤ Long-term durability of TED treatment demonstrated
➤ Positive Phase 1/2 data from study evaluating X-linked retinoschisis
➤ Eye drop recall
➤ ASCRS news and events
➤ NDA submitted to the FDA for presbyopia drop
➤ FDA issues complete response letter to dry eye NDA
➤ FDA accepts BLA resubmission for bevacizumab to treat wet AMD
➤ One-month results in Phase 1/2 trial for treating Leber congenital amaurosis in a pediatric patient
➤ ASCRS news and events
➤ Long-term data on treatment for neuropathic corneal pain
➤ European agency issues positive opinion for low-dose atropine formulation
➤ Study: semaglutide use associated with increased risk of NAION
➤ Company news
➤ ASCRS news and events
➤ Voluntary IOL recall
➤ Phase 4 study assesses patient-reported outcomes of dry eye drop
➤ Study: synthetic opsin restores vision in cases of severe retinal degeneration
➤ Phase 3 endpoints not met in trial evaluating wet AMD treatment
➤ Merger news
➤ ASCRS news and events
➤ 510(k) clearance granted to pattern scanning laser indirect ophthalmoscope
➤ 12-week safety, efficacy results for wet AMD therapy
➤ Phase 3 trial for dry eye treatment complete
➤ Corneal implant company moves toward PMA submission
➤ Update on neuropathic corneal pain trial
➤ ASCRS news and events
➤ NDA submitted for epithelium-on crosslinking therapy
➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis
➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy
➤ Phase 1b study evaluating sozinibercept for DME published
➤ Phase 2 study for topical dry AMD therapy begins
➤ FDA clears IND for gene therapy targeting Stargardt disease
➤ ASCRS news and events
Many patients use drops to help with a variety of ophthalmic issues, however, one thing to consider is the formulation of these products, specifically if they have preservatives. Three ophthalmologists discussed the precautions with preservatives and shared the importance of monitoring for toxicity and potentially finding alternative treatment options.
In December 2020, the FDA issued “Dry Eye: Developing Drugs for Treatment Guidance for Industry” as a draft for public comment. William Boyd, MD, Deputy Division Director with the FDA’s Center for Drug Evaluation and Research, shared with EyeWorld that the administration hopes to issue its final guidance soon.
